Last $46.90 USD
Change Today -0.25 / -0.53%
Volume 398.7K
PKI On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

perkinelmer inc (PKI) Snapshot

Open
$46.91
Previous Close
$47.15
Day High
$47.13
Day Low
$46.64
52 Week High
07/3/14 - $48.26
52 Week Low
10/15/14 - $38.96
Market Cap
5.3B
Average Volume 10 Days
466.7K
EPS TTM
$1.56
Shares Outstanding
113.0M
EX-Date
04/15/15
P/E TM
30.1x
Dividend
$0.28
Dividend Yield
0.60%
Current Stock Chart for PERKINELMER INC (PKI)

perkinelmer inc (PKI) Related Businessweek News

No Related Businessweek News Found

perkinelmer inc (PKI) Details

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The Human Health segment develops diagnostics, tools, and applications to help detect diseases earlier, and to accelerate the discovery and development of critical new therapies. It provides early detection for genetic disorders from pregnancy to early childhood, well as flat panel X-ray detectors and infectious disease testing for the diagnostics market; and a suite of solutions, including reagents, liquid handling systems, and detection and imaging technologies that enable scientists to enhance life sciences research and drug discovery processes. This segment’s research portfolio includes instrumentation for automation and detection solutions, and in vitro and in vivo imaging and analysis hardware and software; and a portfolio of consumable products, including drug discovery and research reagents. The Environmental Health segment provides products, services, and solutions to facilitate the creation of safer food and consumer products. It develops and provides analytical technologies, solutions, and services that enable its customers to understand the characterization and health of various aspects, including air, water, soil, and food. This segment also provides analytical instrumentation for the industrial market, which includes the chemical, petrochemical, lubricant, polymer, electronics, pharmaceutical, and food and dietary supplement industries; and laboratory services. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.

7,700 Employees
Last Reported Date: 02/24/15
Founded in 1931

perkinelmer inc (PKI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $978.3K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $469.6K
Senior Vice President and President of Human ...
Total Annual Compensation: $341.0K
Senior Vice President of Administration, Gene...
Total Annual Compensation: $394.6K
Compensation as of Fiscal Year 2013.

perkinelmer inc (PKI) Key Developments

PerkinElmer Inc. Elects Sylvie Grégoire to its Board of Directors

PerkinElmer Inc. announced that Sylvie Grégoire, Pharm. D., has been elected to its Board of Directors, effective February 6, 2015. With nearly 30 years of industry experience, Dr. Grégoire most recently served as President of Human Genetic Therapies for Shire Plc for seven years. Dr. Grégoire is currently a Board member of Galenica Limited and also served for five years on the Board of Cubist Pharmaceuticals.

PerkinElmer Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2014; Provides Earnings Guidance for the First Quarter of 2015 and Full Year 2015

PerkinElmer Inc. announced consolidated earnings results for the fourth quarter and full year ended December 28, 2014. For the quarter, the company reported revenue of $608,390,000 compared to $591,870,000 a year ago. Operating income from continuing operations was $30,567,000 compared to $92,930,000 a year ago. Income from continuing operations, before income taxes was $20,647,000 compared to $66,065,000 a year ago. Income from continuing operations was $31,314,000 or $0.28 per share compared to $73,455,000 or $0.65 per share a year ago. Net income was $30,787,000 or $0.27 per share compared to $66,873,000 or $0.59 per share a year ago. Adjusted EPS was $0.85 per share compared to $0.74 per share a year ago. Net cash provided by operating activities was $96,564,000 compared to $71,703,000 a year ago. Capital expenditures were $6,858,000 compared to $7,427,000 a year ago. Adjusted operating income was $130.6 million compared to $115.5 million a year ago. Operating cash flow from continuing operations was $282 million versus $157 million in 2013. Improved working capital efficiency and completed operational investments were key drivers to this significant level of improvement. Free cash flow for the fourth quarter was $90 million. For the full year, the company reported revenue of $2,237,219,000 compared to $2,157,586,000 a year ago. Operating income from continuing operations was $210,742,000 compared to $227,794,000 a year ago. Income from continuing operations, before income taxes was $169,603,000 compared to $163,684,000 a year ago. Income from continuing operations was $161,166,000 or $1.42 per share compared to $174,267,000 or $1.54 per share a year ago. Net income was $157,778,000 or $1.39 per share compared to $167,212,000 or $1.47 per share a year ago. Adjusted EPS was $2.47 per share compared to $2.10 per share a year ago. Net cash provided by operating activities was $281,597,000 compared to $158,591,000 a year ago. Capital expenditures were $29,072,000 compared to $38,981,000 a year ago. Adjusted operating income was $394.6 million compared to $347.2 million a year ago. For the full year 2015, the company forecasts GAAP earnings per share from continuing operations in the range of $2.04 to $2.10 and on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share of $2.58 to $2.64. The guidance assumes that the stronger US dollar will negatively impact earnings per share for 2015 by approximately $0.15. The company expects revenue of $2.28 billion to $2.32 billion. The company expects adjusted gross margin expansion of approximately 20 to 30 basis points and adjusted operating margin expansion of 30 to 50 basis points. Net interest expense is expected to be approximately $42 million to $44 million and adjusted tax rate is expected to be 21%. For the first quarter of 2015, the company is forecasting reported revenues to be in the range of $530 million to $540 million or essentially flat that represent organic revenue growth of 3% to 4%. Adjusted earnings per share expects to be in the range of $0.44 to $0.46.

PerkinElmer Seeks Acquisitions

According to the quarter 4 brief of PerkinElmer Inc. (NYSE:PKI), the company expects modest increases in R&D spending throughout 2015 as it continues to invest in innovative new product development. Rob Friel, Chairman and Chief Executive Officer said, "First of all, from our perspective, I think we feel pretty good about the capability we have to continue to do acquisitions, and potentially buy back share as well. I think our slight preference is to do both on acquisitions that add good capability, both from a technology and organizational capability. To the extent we can't find appropriate assets or the valuations are challenging, we would buy back stock."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PKI:US $46.90 USD -0.25

PKI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $45.65 USD -0.66
MEDNAX Inc $70.57 USD -0.66
QIAGEN NV €22.17 EUR -0.038
Sirona Dental Systems Inc $91.22 USD -0.88
Teleflex Inc $122.41 USD -0.50
View Industry Companies
 

Industry Analysis

PKI

Industry Average

Valuation PKI Industry Range
Price/Earnings 33.3x
Price/Sales 2.4x
Price/Book 2.6x
Price/Cash Flow 33.8x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERKINELMER INC, please visit www.perkinelmer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.